|
Market Closed -
Hong Kong S.E.
11:08:09 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.130 HKD | -0.63% |
|
+4.33% | +6.10% |
| 08-31 | HighTide Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 07-02 | HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns | MT |
Company Valuation: HighTide Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Market Cap 1 | 6,056 | 614.3 | 1,515 |
| Change | - | -89.86% | 146.54% |
| Enterprise Value (EV) 1 | 5,336 | 201.5 | 1,139 |
| Change | - | -96.22% | 464.94% |
| P/E | -3.25x | -1.41x | -5.19x |
| PBR | 8.62x | 1.45x | 4.93x |
| PEG | 0.2x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -11.9x | -0.45x | -5.13x |
| EV / EBIT | -11.9x | -0.45x | -5.09x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -3.617 | -0.8445 | -0.5106 |
| Distribution rate | - | - | - |
| Net sales | - | - | - |
| EBITDA 1 | -447.7 | -443.7 | -222.2 |
| EBIT 1 | -448.2 | -444.8 | -223.6 |
| Net income 1 | -939.3 | -381.8 | -245 |
| Net Debt 1 | -719.9 | -412.8 | -376 |
| Reference price 2 | 11.764 | 1.193 | 2.651 |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | 571,326 |
| Announcement Date | 4/26/24 A | 4/23/25 A | 4/29/26 A |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 230M | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| Average | 26.74x | 26.52x | 15.69x | 0.32% | 38.21B | |
| Weighted average by Cap. | 26.71x | 25.51x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2511 Stock
- Valuation HighTide Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
